

Zwi N Berneman

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6766100/publications.pdf>

Version: 2024-02-01

184
papers

7,997
citations

53794

45
h-index

60623

81
g-index

187
all docs

187
docs citations

187
times ranked

10321
citing authors

#	ARTICLE	IF	CITATIONS
1	Clinical use of dendritic cells for cancer therapy. <i>Lancet Oncology</i> , The, 2014, 15, e257-e267.	10.7	565
2	Prevalence, determinants, and outcomes of nonadherence to imatinib therapy in patients with chronic myeloid leukemia: the ADAGIO study. <i>Blood</i> , 2009, 113, 5401-5411.	1.4	540
3	Highly efficient gene delivery by mRNA electroporation in human hematopoietic cells: superiority to lipofection and passive pulsing of mRNA and to electroporation of plasmid cDNA for tumor antigen loading of dendritic cells. <i>Blood</i> , 2001, 98, 49-56.	1.4	438
4	Cellular and molecular neuropathology of the cuprizone mouse model: Clinical relevance for multiple sclerosis. <i>Neuroscience and Biobehavioral Reviews</i> , 2014, 47, 485-505.	6.1	352
5	Induction of complete and molecular remissions in acute myeloid leukemia by Wilms's tumor 1 antigen-targeted dendritic cell vaccination. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2010, 107, 13824-13829.	7.1	341
6	Balancing between immunity and tolerance: an interplay between dendritic cells, regulatory T cells, and effector T cells. <i>Journal of Leukocyte Biology</i> , 2007, 82, 1365-1374.	3.3	192
7	The Use of TLR7 and TLR8 Ligands for the Enhancement of Cancer Immunotherapy. <i>Oncologist</i> , 2008, 13, 859-875.	3.7	192
8	Dendritic cell vaccination as postremission treatment to prevent or delay relapse in acute myeloid leukemia. <i>Blood</i> , 2017, 130, 1713-1721.	1.4	170
9	High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. <i>Journal of Clinical Oncology</i> , 2014, 32, 219-228.	1.6	145
10	The Paradox of Platelet Activation and Impaired Function: Platelet-von Willebrand Factor Interactions, and the Etiology of Thrombotic and Hemorrhagic Manifestations in Essential Thrombocythemia and Polycythemia Vera. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 589-604.	2.7	139
11	Regulatory T Cells and Human Disease. <i>Clinical and Developmental Immunology</i> , 2007, 2007, 1-10.	3.3	139
12	Dendritic Cells as Pharmacological Tools for Cancer Immunotherapy. <i>Pharmacological Reviews</i> , 2015, 67, 731-753.	16.0	129
13	Clinical-grade manufacturing of autologous mature mRNA-electroporated dendritic cells and safety testing in acute myeloid leukemia patients in a phase I dose-escalation clinical trial. <i>Cytotherapy</i> , 2009, 11, 653-668.	0.7	98
14	Results of a phase I/II clinical trial: standardized, non-xenogenic, cultivated limbal stem cell transplantation. <i>Journal of Translational Medicine</i> , 2014, 12, 58.	4.4	96
15	Interleukin-15 enhances the proliferation, stimulatory phenotype, and antitumor effector functions of human gamma delta T cells. <i>Journal of Hematology and Oncology</i> , 2016, 9, 101.	17.0	96
16	Clinical and Laboratory Features, Pathobiology of Platelet-Mediated Thrombosis and Bleeding Complications, and the Molecular Etiology of Essential Thrombocythemia and Polycythemia Vera: Therapeutic Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 174-207.	2.7	94
17	mRNA-based dendritic cell vaccination induces potent antiviral T-cell responses in HIV-1-infected patients. <i>Aids</i> , 2012, 26, F1-F12.	2.2	88
18	Safety and clinical efficacy of BCMA CAR-T-cell therapy in multiple myeloma. <i>Journal of Hematology and Oncology</i> , 2020, 13, 164.	17.0	88

#	ARTICLE	IF	CITATIONS
19	Reporter gene-expressing bone marrow-derived stromal cells are immune-tolerated following implantation in the central nervous system of syngeneic immunocompetent mice. <i>BMC Biotechnology</i> , 2009, 9, 1.	3.3	78
20	Sequential Combination of Gemtuzumab Ozogamicin and Standard Chemotherapy in Older Patients With Newly Diagnosed Acute Myeloid Leukemia: Results of a Randomized Phase III Trial by the EORTC and GIMEMA Consortium (AML-17). <i>Journal of Clinical Oncology</i> , 2013, 31, 4424-4430.	1.6	78
21	NK Cells: Key to Success of DC-Based Cancer Vaccines?. <i>Oncologist</i> , 2012, 17, 1256-1270.	3.7	76
22	Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical Trials. <i>Oncologist</i> , 2012, 17, 250-259.	3.7	75
23	Current Challenges for the Advancement of Neural Stem Cell Biology and Transplantation Research. <i>Stem Cell Reviews and Reports</i> , 2012, 8, 262-278.	5.6	75
24	3D culture of murine neural stem cells on decellularized mouse brain sections. <i>Biomaterials</i> , 2015, 41, 122-131.	11.4	75
25	Short-term cultured, interleukin-15 differentiated dendritic cells have potent immunostimulatory properties. <i>Journal of Translational Medicine</i> , 2009, 7, 109.	4.4	74
26	Chimeric Antigen Receptor-Modified T Cell Therapy in Multiple Myeloma: Beyond B Cell Maturation Antigen. <i>Frontiers in Immunology</i> , 2019, 10, 1613.	4.8	70
27	Dendritic Cell-Based Cancer Gene Therapy. <i>Human Gene Therapy</i> , 2009, 20, 1106-1118.	2.7	68
28	Tolerogenic dendritic cell-based treatment for multiple sclerosis (MS): a harmonised study protocol for two phase I clinical trials comparing intradermal and intranodal cell administration. <i>BMJ Open</i> , 2019, 9, e030309.	1.9	63
29	mRNA-based gene transfer as a tool for gene and cell therapy. <i>Current Opinion in Molecular Therapeutics</i> , 2007, 9, 423-31.	2.8	61
30	SARS-CoV-2 and cancer: Are they really partners in crime?. <i>Cancer Treatment Reviews</i> , 2020, 89, 102068.	7.7	60
31	Microarray analyses in dendritic cells reveal potential biomarkers for chemical-induced skin sensitization. <i>Molecular Immunology</i> , 2007, 44, 3222-3233.	2.2	59
32	Messenger RNA Electroporation of Human Monocytes, Followed by Rapid In Vitro Differentiation, Leads to Highly Stimulatory Antigen-Loaded Mature Dendritic Cells. <i>Journal of Immunology</i> , 2002, 169, 1669-1675.	0.8	56
33	Efficient stimulation of HIV-1-specific T cells using dendritic cells electroporated with mRNA encoding autologous HIV-1 Gag and Env proteins. <i>Blood</i> , 2006, 107, 1818-1827.	1.4	56
34	Dendritic Cells: Cellular Mediators for Immunological Tolerance. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-8.	3.3	56
35	The 2001 World Health Organization and Updated European Clinical and Pathological Criteria for the Diagnosis, Classification, and Staging of the Philadelphia Chromosome-Negative Chronic Myeloproliferative Disorders. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 307-340.	2.7	55
36	Standardized Limbal Epithelial Stem Cell Graft Generation and Transplantation. <i>Tissue Engineering - Part C: Methods</i> , 2010, 16, 921-927.	2.1	54

#	ARTICLE	IF	CITATIONS
37	Trial watch: Dendritic cell (DC)-based immunotherapy for cancer. <i>OncImmunology</i> , 2022, 11, .	4.6	54
38	Interleukin-13 immune gene therapy prevents CNS inflammation and demyelination via alternative activation of microglia and macrophages. <i>Glia</i> , 2016, 64, 2181-2200.	4.9	53
39	The Toll-like receptor 7/8 agonist resiquimod greatly increases the immunostimulatory capacity of human acute myeloid leukemia cells. <i>Cancer Immunology, Immunotherapy</i> , 2010, 59, 35-46.	4.2	51
40	Response of von Willebrand Factor Parameters to Desmopressin in Patients with Type 1 and Type 2 Congenital von Willebrand Disease: Diagnostic and Therapeutic Implications. <i>Seminars in Thrombosis and Hemostasis</i> , 2002, 28, 111-132.	2.7	50
41	Plasmid-based genetic modification of human bone marrow-derived stromal cells: analysis of cell survival and transgene expression after transplantation in rat spinal cord. <i>BMC Biotechnology</i> , 2007, 7, 90.	3.3	50
42	Dendritic cell vaccination in acute myeloid leukemia. <i>Cytotherapy</i> , 2012, 14, 647-656.	0.7	49
43	Dendritic Cell-Based Immunotherapy of Acute Myeloid Leukemia. <i>Journal of Clinical Medicine</i> , 2019, 8, 579.	2.4	48
44	Interleukin-15-Induced CD56+ Myeloid Dendritic Cells Combine Potent Tumor Antigen Presentation with Direct Tumoricidal Potential. <i>PLoS ONE</i> , 2012, 7, e51851.	2.5	48
45	Immunotherapy of Acute Myeloid Leukemia: Current Approaches. <i>Oncologist</i> , 2009, 14, 240-252.	3.7	47
46	Interleukin-15 Dendritic Cells Harness NK Cell Cytotoxic Effector Function in a Contact- and IL-15-Dependent Manner. <i>PLoS ONE</i> , 2015, 10, e0123340.	2.5	47
47	WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders. <i>Leukemia Research</i> , 2007, 31, 1031-1038.	0.8	46
48	Neuroendocrine Immunoregulation in Multiple Sclerosis. <i>Clinical and Developmental Immunology</i> , 2013, 2013, 1-23.	3.3	46
49	12 Weeks of Combined Endurance and Resistance Training Reduces Innate Markers of Inflammation in a Randomized Controlled Clinical Trial in Patients with Multiple Sclerosis. <i>Mediators of Inflammation</i> , 2016, 2016, 1-13.	3.0	46
50	Clinical Potential of Intravenous Neural Stem Cell Delivery for Treatment of Neuroinflammatory Disease in Mice?. <i>Cell Transplantation</i> , 2011, 20, 851-870.	2.5	45
51	Optimizing Dendritic Cell-Based Immunotherapy: Tackling the Complexity of Different Arms of the Immune System. <i>Mediators of Inflammation</i> , 2012, 2012, 1-14.	3.0	42
52	Cryopreserved vitamin D3-tolerogenic dendritic cells pulsed with autoantigens as a potential therapy for multiple sclerosis patients. <i>Journal of Neuroinflammation</i> , 2016, 13, 113.	7.2	42
53	To the Brain and Back: Migratory Paths of Dendritic Cells in Multiple Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 178-192.	1.7	42
54	A systematic review on poly(I:C) and poly-ICLC in glioblastoma: adjuvants coordinating the unlocking of immunotherapy. <i>Journal of Experimental and Clinical Cancer Research</i> , 2021, 40, 213.	8.6	42

#	ARTICLE	IF	CITATIONS
55	Laboratory Diagnosis and Molecular Classification of von Willebrand Disease. <i>Acta Haematologica</i> , 2009, 121, 71-84.	1.4	41
56	Changing Concepts of Diagnostic Criteria of Myeloproliferative Disorders and the Molecular Etiology and Classification of Myeloproliferative Neoplasms: From Dameshek 1950 to Vainchenker 2005 and Beyond. <i>Acta Haematologica</i> , 2015, 133, 36-51.	1.4	39
57	Transpresentation of interleukin-15 by IL-15/IL-15R α mRNA-engineered human dendritic cells boosts antitumoral natural killer cell activity. <i>Oncotarget</i> , 2015, 6, 44123-44133.	1.8	39
58	Poly(I:C) primes primary human glioblastoma cells for an immune response invigorated by PD-L1 blockade. <i>Oncolmmunology</i> , 2018, 7, e1407899.	4.6	38
59	Interleukin-15-Cultured Dendritic Cells Enhance Anti-Tumor Gamma Delta T Cell Functions through IL-15 Secretion. <i>Frontiers in Immunology</i> , 2018, 9, 658.	4.8	38
60	Flow Cytometric Analysis of Erythrocytic Blood Group A Antigen Density Profile. <i>Vox Sanguinis</i> , 1991, 61, 265-274.	1.5	37
61	Quantitative and phenotypic analysis of mesenchymal stromal cell graft survival and recognition by microglia and astrocytes in mouse brain. <i>Immunobiology</i> , 2013, 218, 696-705.	1.9	37
62	Cell Type-Associated Differences in Migration, Survival, and Immunogenicity following Grafting in CNS Tissue. <i>Cell Transplantation</i> , 2012, 21, 1867-1881.	2.5	36
63	Induction of Cytomegalovirus-Specific T Cell Responses in Healthy Volunteers and Allogeneic Stem Cell Recipients Using Vaccination With Messenger RNA-Transfected Dendritic Cells. <i>Transplantation</i> , 2015, 99, 120-127.	1.0	36
64	Monocyte-Derived Dendritic Cells with Silenced PD-1 Ligands and Transpresenting Interleukin-15 Stimulate Strong Tumor-Reactive T-cell Expansion. <i>Cancer Immunology Research</i> , 2017, 5, 710-715.	3.4	36
65	Triple-negative breast cancer Role of immunology: A systemic review. <i>Breast Journal</i> , 2020, 26, 995-999.	1.0	36
66	Allogeneic stromal cell implantation in brain tissue leads to robust microglial activation. <i>Immunology and Cell Biology</i> , 2009, 87, 267-273.	2.3	35
67	Flow Cytometric Analysis of Erythrocytic D Antigen Density Profile. <i>Vox Sanguinis</i> , 1986, 51, 40-46.	1.5	34
68	Dendritic cells in the pathogenesis and treatment of human diseases: a Janus Bifrons?. <i>Immunotherapy</i> , 2011, 3, 1203-1222.	2.0	34
69	Spatiotemporal evolution of early innate immune responses triggered by neural stem cell grafting. <i>Stem Cell Research and Therapy</i> , 2012, 3, 56.	5.5	34
70	Human Tears Reveal Insights into Corneal Neovascularization. <i>PLoS ONE</i> , 2012, 7, e36451.	2.5	34
71	Intracerebral transplantation of interleukin 13-producing mesenchymal stem cells limits microgliosis, oligodendrocyte loss and demyelination in the cuprizone mouse model. <i>Journal of Neuroinflammation</i> , 2016, 13, 288.	7.2	34
72	Concise Review: Innate and Adaptive Immune Recognition of Allogeneic and Xenogeneic Cell Transplants in the Central Nervous System. <i>Stem Cells Translational Medicine</i> , 2017, 6, 1434-1441.	3.3	34

#	ARTICLE	IF	CITATIONS
73	Gene expression signatures in CD34+-progenitor-derived dendritic cells exposed to the chemical contact allergen nickel sulfate. <i>Toxicology and Applied Pharmacology</i> , 2006, 216, 131-149.	2.8	33
74	Interferon $\hat{\pm}$ may be back on track to treat acute myeloid leukemia. <i>Oncolmmunology</i> , 2013, 2, e23619.	4.6	33
75	RHAMM/HMMR (CD168) is not an ideal target antigen for immunotherapy of acute myeloid leukemia. <i>Haematologica</i> , 2012, 97, 1539-1547.	3.5	32
76	Poly(I:C) Enhances the Susceptibility of Leukemic Cells to NK Cell Cytotoxicity and Phagocytosis by DC. <i>PLoS ONE</i> , 2011, 6, e20952.	2.5	31
77	Circulating dendritic cells of multiple sclerosis patients are proinflammatory and their frequency is correlated with MS-associated genetic risk factors. <i>Multiple Sclerosis Journal</i> , 2014, 20, 548-557.	3.0	31
78	Dendritic cell vaccine therapy for acute myeloid leukemia: Questions and answers. <i>Hum Vaccin</i> , 2011, 7, 579-584.	2.4	30
79	Distinct spatial distribution of microglia and macrophages following mesenchymal stem cell implantation in mouse brain. <i>Immunology and Cell Biology</i> , 2014, 92, 650-658.	2.3	30
80	Neuroprotective modulation of microglia effector functions following priming with interleukin 4 and 13: current limitations in understanding their mode-of-action. <i>Brain, Behavior, and Immunity</i> , 2020, 88, 856-866.	4.1	30
81	Efficient and Non-genotoxic RNA-Based Engineering of Human T Cells Using Tumor-Specific T Cell Receptors With Minimal TCR Mispairing. <i>Frontiers in Immunology</i> , 2018, 9, 2503.	4.8	29
82	Interleukin-15 dendritic cells as vaccine candidates for cancer immunotherapy. <i>Human Vaccines and Immunotherapeutics</i> , 2013, 9, 1956-1961.	3.3	28
83	Induction of complete remission of acute myeloid leukaemia by pegylated interferon $\hat{\pm}$ 2a in a patient with transformed primary myelofibrosis. <i>British Journal of Haematology</i> , 2010, 149, 152-155.	2.5	27
84	Engineering monocyte-derived dendritic cells to secrete interferon- $\hat{\pm}$ enhances their ability to promote adaptive and innate anti-tumor immune effector functions. <i>Cancer Immunology, Immunotherapy</i> , 2015, 64, 831-842.	4.2	27
85	Cytokine transcript profiling in CD34+-progenitor derived dendritic cells exposed to contact allergens and irritants. <i>Toxicology Letters</i> , 2005, 155, 187-194.	0.8	26
86	Platelet-mediated thrombotic complications in patients with ET: Reversal by aspirin, platelet reduction, and not by coumadin. <i>Blood Cells, Molecules, and Diseases</i> , 2006, 36, 199-205.	1.4	26
87	Aspirin-Responsive, Migraine-Like Transient Cerebral and Ocular Ischemic Attacks and Erythromelalgia in JAK2^{V617F}-Positive Essential Thrombocythemia and Polycythemia Vera. <i>Acta Haematologica</i> , 2015, 133, 56-63.	1.4	26
88	Capacity of CD34+ progenitor-derived dendritic cells to distinguish between sensitizers and irritants. <i>Toxicology Letters</i> , 2005, 156, 377-389.	0.8	25
89	Clinical and microbiological impact of discontinuation of fluoroquinolone prophylaxis in patients with prolonged profound neutropenia. <i>European Journal of Haematology</i> , 2014, 93, 302-308.	2.2	25
90	Recognition of cellular implants by the brain's innate immune system. <i>Immunology and Cell Biology</i> , 2011, 89, 511-516.	2.3	23

#	ARTICLE	IF	CITATIONS
91	Tackling the physiological barriers for successful mesenchymal stem cell transplantation into the central nervous system. <i>Stem Cell Research and Therapy</i> , 2013, 4, 101.	5.5	23
92	Managing Patients with von Willebrand Disease Type 1, 2 and 3 with Desmopressin and von Willebrand Factor-Factor VIII Concentrate in Surgical Settings. <i>Acta Haematologica</i> , 2009, 121, 167-176.	1.4	22
93	Laboratory Diagnosis of von Willebrand Disease Type 1/2E (2A Subtype IIE), Type 1 Vicenza and Mild Type 1 Caused by Mutations in the D3, D4, B1 and C1 Domains of the von Willebrand Factor Gene. <i>Acta Haematologica</i> , 2009, 121, 128-138.	1.4	21
94	Labeling of Luciferase/eGFP-Expressing Bone Marrow-Derived Stromal Cells with Fluorescent Micron-Sized Iron Oxide Particles Improves Quantitative and Qualitative Multimodal Imaging of Cellular Grafts In Vivo. <i>Molecular Imaging and Biology</i> , 2011, 13, 1133-1145.	2.6	21
95	Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells. <i>Journal of Translational Medicine</i> , 2022, 20, 124.	4.4	21
96	Safety and Efficacy of Antibiotic De-escalation and Discontinuation in High-Risk Hematological Patients With Febrile Neutropenia: A Single-Center Experience. <i>Open Forum Infectious Diseases</i> , 2022, 9, ofab624.	0.9	21
97	Cuprizone-induced demyelination and demyelination-associated inflammation result in different proton magnetic resonance metabolite spectra. <i>NMR in Biomedicine</i> , 2015, 28, 505-513.	2.8	20
98	Clinical and immunological control of experimental autoimmune encephalomyelitis by tolerogenic dendritic cells loaded with MOG-encoding mRNA. <i>Journal of Neuroinflammation</i> , 2019, 16, 167.	7.2	20
99	Immunological response after therapeutic vaccination with WT1 mRNA-loaded dendritic cells in end-stage endometrial carcinoma. <i>Anticancer Research</i> , 2010, 30, 3709-14.	1.1	20
100	Early Inflammatory Responses following Cell Grafting in the CNS Trigger Activation of the Subventricular Zone: A Proposed Model of Sequential Cellular Events. <i>Cell Transplantation</i> , 2015, 24, 1481-1492.	2.5	19
101	Murine iPSC-derived microglia and macrophage cell culture models recapitulate distinct phenotypical and functional properties of classical and alternative neuro-immune polarisation. <i>Brain, Behavior, and Immunity</i> , 2019, 82, 406-421.	4.1	19
102	Highly Efficient mRNA-Based Gene Transfer in Feeder-Free Cultured H9 Human Embryonic Stem Cells. <i>Cloning and Stem Cells</i> , 2004, 6, 211-216.	2.6	18
103	Immunomodulatory Effects of 1,25-Dihydroxyvitamin D3 on Dendritic Cells Promote Induction of T Cell Hyporesponsiveness to Myelin-Derived Antigens. <i>Journal of Immunology Research</i> , 2016, 2016, 1-16.	2.2	18
104	The Ins and Outs of Messenger RNA Electroporation for Physical Gene Delivery in Immune Cell-Based Therapy. <i>Pharmaceutics</i> , 2021, 13, 396.	4.5	18
105	Desirable cytolytic immune effector cell recruitment by interleukin-15 dendritic cells. <i>Oncotarget</i> , 2017, 8, 13652-13665.	1.8	18
106	Efficient generation of stably electrotransfected human hematopoietic cell lines without drug selection by consecutive FACS sorting. <i>Cytometry</i> , 2000, 41, 31-35.	1.8	17
107	Efficient removal of LoxP-flanked genes by electroporation of Cre-recombinase mRNA. <i>Biochemical and Biophysical Research Communications</i> , 2003, 305, 10-15.	2.1	17
108	Role of Dendritic Cells in HIV-Immunotherapy. <i>Current HIV Research</i> , 2010, 8, 310-322.	0.5	17

#	ARTICLE	IF	CITATIONS
109	Optical Coherence Tomography in Cultivated Limbal Epithelial Stem Cell Transplantation Surgery. <i>Asia-Pacific Journal of Ophthalmology</i> , 2015, 4, 339-345.	2.5	17
110	In Vivo Interleukin-13-Primed Macrophages Contribute to Reduced Alloantigen-Specific T Cell Activation and Prolong Immunological Survival of Allogeneic Mesenchymal Stem Cell Implants. <i>Stem Cells</i> , 2016, 34, 1971-1984.	3.2	17
111	CMRF-56 ⁺ blood dendritic cells loaded with mRNA induce effective antigen-specific cytotoxic T-lymphocyte responses. <i>Oncology</i> , 2016, 5, e1168555.	4.6	17
112	The tumor-associated antigen RHAMM (HMMR/CD168) is expressed by monocyte-derived dendritic cells and presented to T cells. <i>Oncotarget</i> , 2016, 7, 73960-73970.	1.8	17
113	A versatile T cell-based assay to assess therapeutic antigen-specific PD-1-targeted approaches. <i>Oncotarget</i> , 2018, 9, 27797-27808.	1.8	17
114	Dominant von Willebrand Disease Type 2M and 2U Are Variable Expressions of One Distinct Disease Entity Caused by Loss-of-Function Mutations in the A1 Domain of the von Willebrand Factor Gene. <i>Acta Haematologica</i> , 2009, 121, 145-153.	1.4	16
115	Stem cell therapy for multiple sclerosis: preclinical evidence beyond all doubt?. <i>Regenerative Medicine</i> , 2012, 7, 245-259.	1.7	16
116	Increased Transendothelial Transport of CCL3 Is Insufficient to Drive Immune Cell Transmigration through the Blood-Brain Barrier under Inflammatory Conditions In Vitro. <i>Mediators of Inflammation</i> , 2017, 2017, 1-11.	3.0	16
117	Antigen-Specific Treatment Modalities in MS: The Past, the Present, and the Future. <i>Frontiers in Immunology</i> , 2021, 12, 624685.	4.8	15
118	Enhancement of TAT-induced transactivation of the HIV-1 LTR by two genomic fragments of HHV-6. , 1996, 50, 20-24.		14
119	Immunoglobulin G/total antibody testing for SARS-CoV-2: A prospective cohort study of ambulatory patients and health care workers in two Belgian oncology units comparing three commercial tests. <i>European Journal of Cancer</i> , 2021, 148, 328-339.	2.8	14
120	Flow cytometric analysis of hairy cell leukemia using right-angle light scatter. <i>Cytometry</i> , 1986, 7, 217-220.	1.8	13
121	Dendritic Cell-Based and Other Vaccination Strategies for Pediatric Cancer. <i>Cancers</i> , 2019, 11, 1396.	3.7	13
122	Simultaneous Activation of Viral Antigen-specific Memory CD4+ and CD8+ T-cells Using mRNA-electroporated CD40-activated Autologous B-cells. <i>Journal of Immunotherapy</i> , 2006, 29, 512-523.	2.4	12
123	The effect of apoptotic cells on virus-specific immune responses detected using IFN-gamma ELISPOT. <i>Journal of Immunological Methods</i> , 2010, 357, 51-54.	1.4	12
124	GMP-Grade mRNA Electroporation of Dendritic Cells for Clinical Use. <i>Methods in Molecular Biology</i> , 2016, 1428, 139-150.	0.9	12
125	Rapid Assessment of Functional Avidity of Tumor-Specific T Cell Receptors Using an Antigen-Presenting Tumor Cell Line Electroporated with Full-Length Tumor Antigen mRNA. <i>Cancers</i> , 2020, 12, 256.	3.7	12
126	Acute myeloid leukemic cell lines loaded with synthetic dsRNA trigger IFN- γ secretion by human NK cells. <i>Leukemia Research</i> , 2009, 33, 539-546.	0.8	11

#	ARTICLE	IF	CITATIONS
127	Adult acute precursor B-cell lymphoblastic leukemia presenting as hypercalcemia and osteolytic bone lesions. <i>Experimental Hematology and Oncology</i> , 2017, 6, 9.	5.0	11
128	Cellular Immunotherapy for Cytomegalovirus and HIV-1 Infection. <i>Journal of Immunotherapy</i> , 2006, 29, 107-121.	2.4	10
129	Guidelines for the Evaluation of Intravenous Desmopressin and von Willebrand Factor/Factor VIII Concentrate in the Treatment and Prophylaxis of Bleedings in von Willebrand Disease Types 1, 2, and 3. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 636-645.	2.7	10
130	Immunotherapy of hematological malignancies using dendritic cells. <i>Bulletin Du Cancer</i> , 2008, 95, 320-6.	1.6	10
131	Altered molecular expression of TLR-signaling pathways affects the steady-state release of IL-12p70 and IFN- γ in patients with relapsing-remitting multiple sclerosis. <i>Innate Immunity</i> , 2016, 22, 266-273.	2.4	9
132	Immune remodelling of stromal cell grafts in the central nervous system: therapeutic inflammation or (harmless) side-effect?. <i>Journal of Tissue Engineering and Regenerative Medicine</i> , 2017, 11, 2846-2852.	2.7	9
133	Laboratory Diagnosis and Molecular Basis of Mild von Willebrand Disease Type 1. <i>Acta Haematologica</i> , 2009, 121, 85-97.	1.4	8
134	Laboratory and Molecular Characteristics of Recessive von Willebrand Disease Type 2C (2A Subtype IIC) of Variable Severity due to Homozygous or Double Heterozygous Mutations in the D1 and D2 Domains. <i>Acta Haematologica</i> , 2009, 121, 111-118.	1.4	8
135	Injury-Dependent Retention of Intraportally Administered Mesenchymal Stromal Cells Following Partial Hepatectomy of Steatotic Liver Does Not Lead to Improved Liver Recovery. <i>PLoS ONE</i> , 2013, 8, e69092.	2.5	8
136	Except for C-C chemokine receptor 7 expression, monocyte-derived dendritic cells from patients with multiple sclerosis are functionally comparable to those of healthy controls. <i>Cytotherapy</i> , 2014, 16, 1024-1030.	0.7	8
137	Rapid Exercise-Induced Mobilization of Dendritic Cells Is Potentially Mediated by a Flt3L- and MMP-9-Dependent Process in Multiple Sclerosis. <i>Mediators of Inflammation</i> , 2015, 2015, 1-10.	3.0	8
138	Shuttling Tolerogenic Dendritic Cells across the Blood-Brain Barrier In Vitro via the Introduction of De Novo CCR5 Chemokine Receptor 5 Expression Using Messenger RNA Electroporation. <i>Frontiers in Immunology</i> , 2018, 8, 1964.	4.8	8
139	Absence of BCL-2 Expression Identifies a Subgroup of AML with Distinct Phenotypic, Molecular, and Clinical Characteristics. <i>Journal of Clinical Medicine</i> , 2020, 9, 3090.	2.4	8
140	Immunogenicity and Antileukemic Activity of Dendritic Cells Electroporated with Wilms' Tumor WT1 mRNA: A Phase I/II Trial in Acute Myeloid Leukemia. <i>Blood</i> , 2008, 112, 830-830.	1.4	8
141	Recessive von Willebrand Disease Type 2 Normandy: Variable Expression of Mild Hemophilia and VWD Type 1. <i>Acta Haematologica</i> , 2009, 121, 119-127.	1.4	7
142	CD56 Homodimerization and Participation in Anti-Tumor Immune Effector Cell Functioning: A Role for Interleukin-15. <i>Cancers</i> , 2019, 11, 1029.	3.7	7
143	COMPARISON OF THE POWER OF PROCALCITONIN AND C-REACTIVE PROTEIN TO DISCRIMINATE BETWEEN DIFFERENT AETIOLOGIES OF FEVER IN PROLONGED PROFOUND NEUTROPENIA: A SINGLE-CENTRE PROSPECTIVE OBSERVATIONAL STUDY.. <i>Mediterranean Journal of Hematology and Infectious Diseases</i> , 2019, 11, e2019023.	1.3	7
144	Histological Characterization and Quantification of Cellular Events Following Neural and Fibroblast(-Like) Stem Cell Grafting in Healthy and Demyelinated CNS Tissue. <i>Methods in Molecular Biology</i> , 2014, 1213, 265-283.	0.9	7

#	ARTICLE	IF	CITATIONS
145	Multimodal Imaging of Stem Cell Implantation in the Central Nervous System of Mice. <i>Journal of Visualized Experiments</i> , 2012, , e3906.	0.3	6
146	Autologous T cells on the attack against AML. <i>Blood</i> , 2012, 120, 1151-1152.	1.4	6
147	Quantitative Evaluation of Stem Cell Grafting in the Central Nervous System of Mice by In Vivo Bioluminescence Imaging and Postmortem Multicolor Histological Analysis. <i>Methods in Molecular Biology</i> , 2013, 1052, 125-141.	0.9	6
148	Distinct In Vitro Properties of Embryonic and Extraembryonic Fibroblast-Like Cells are Reflected in their in Vivo Behavior following Grafting in the Adult Mouse Brain. <i>Cell Transplantation</i> , 2015, 24, 223-233.	2.5	6
149	Bone matrix vesicle-bound alkaline phosphatase for the assessment of peripheral blood admixture to human bone marrow aspirates. <i>Clinica Chimica Acta</i> , 2015, 446, 253-260.	1.1	6
150	Generation and Cryopreservation of Clinical Grade Wilmsâ€™ Tumor 1 mRNA-Loaded Dendritic Cell Vaccines for Cancer Immunotherapy. <i>Methods in Molecular Biology</i> , 2016, 1393, 27-35.	0.9	6
151	Interruption or Discontinuation of Tyrosine Kinase Inhibitor Treatment in Chronic Myeloid Leukaemia: A Retrospective Cohort Study (SPARKLE) in Belgium. <i>Acta Haematologica</i> , 2019, 142, 197-207.	1.4	6
152	Functional consequences of a close encounter between microglia and brain-infiltrating monocytes during CNS pathology and repair. <i>Journal of Leukocyte Biology</i> , 2021, 110, 89-106.	3.3	6
153	Transmigration across a Steady-State Bloodâ€™Brain Barrier Induces Activation of Circulating Dendritic Cells Partly Mediated by Actin Cytoskeletal Reorganization. <i>Membranes</i> , 2021, 11, 700.	3.0	6
154	WT1-Targeted Dendritic Cell Vaccination as A Post-Remission Treatment to Prevent Full Relapse In Acute Myeloid Leukemia. <i>Blood</i> , 2010, 116, 16-16.	1.4	6
155	Expression and localization of CHODL ¹ E/CHODL ¹ E, the soluble isoform of chondrolectin. <i>Cell Biology International</i> , 2007, 31, 1323-1330.	3.0	5
156	Interleukin-12p70 Expression by Dendritic Cells of HIV-1-Infected Patients Fails to Stimulate gag-Specific Immune Responses. <i>Clinical and Developmental Immunology</i> , 2012, 2012, 1-11.	3.3	5
157	mRNA Electroporation as a Tool for Immunomonitoring. <i>Methods in Molecular Biology</i> , 2013, 969, 293-303.	0.9	5
158	The European Clinical, Molecular, and Pathological (ECMP) Criteria and the 2007/2008 Revisions of the World Health Organization for the Diagnosis, Classification, and Staging of Prefibrotic Myeloproliferative Neoplasms Carrying the JAK2V617F Mutation. <i>Turkish Journal of Haematology</i> , 2014, , 239-254.	0.5	5
159	Analysis of von Willebrand Disease in the South Moravian Population (Czech Republic): Results from the BRNO-VWD Study. <i>Thrombosis and Haemostasis</i> , 2019, 119, 594-605.	3.4	5
160	Vaccination with WT1 mRNA-Electroporated Dendritic Cells: Report of Clinical Outcome in 66 Cancer Patients. <i>Blood</i> , 2014, 124, 310-310.	1.4	5
161	Luminescent Human iPSC-Derived Neurospheroids Enable Modeling of Neurotoxicity After Oxygenâ€™glucose Deprivation. <i>Neurotherapeutics</i> , 2022, 19, 550-569.	4.4	5
162	Viral infections following allogeneic stem cell transplantation: how to cure the cure?. <i>Leukemia and Lymphoma</i> , 2010, 51, 965-966.	1.3	4

#	ARTICLE	IF	CITATIONS
163	The immunologic aspects in hormone receptor positive breast cancer. <i>Cancer Treatment and Research Communications</i> , 2020, 25, 100207.	1.7	4
164	Murine induced pluripotent stem cellâ€ derived neuroimmune cell culture models emphasize opposite immuneâ€ effector functions of interleukin 13â€ primed microglia and macrophages in terms of neuroimmune toxicity. <i>Glia</i> , 2021, 69, 326-345.	4.9	4
165	Engineering of regulatory T cells by means of mRNA electroporation in a GMP-compliant manner. <i>Cytotherapy</i> , 2022, , .	0.7	4
166	Lymphangiogenesis May Play a Role in Cultivated Limbal Stem Cell Transplant Rejection. <i>Ocular Immunology and Inflammation</i> , 2012, 20, 381-383.	1.8	3
167	Ribonucleic Acid Engineering of Dendritic Cells for Therapeutic Vaccination: Ready â€ Able to Improve Clinical Outcome?. <i>Cancers</i> , 2020, 12, 299.	3.7	2
168	Vaccination of Acute Myeloid Leukemia Patients with Dendritic Cells Electroporated with mRNA Encoding the Wilmsâ€™ Tumor Protein WT1: A Phase I/II Trial.. <i>Blood</i> , 2007, 110, 158-158.	1.4	2
169	Open label phase I/II study of Wilms' tumor gene 1 (WT1) mRNA-transfected autologous dendritic cell vaccination in patients with solid tumors.. <i>Journal of Clinical Oncology</i> , 2012, 30, e13051-e13051.	1.6	2
170	Anti-Tumor Potency of Short-Term Interleukin-15 Dendritic Cells Is Potentiated by In Situ Silencing of Programmed-Death Ligands. <i>Frontiers in Immunology</i> , 2022, 13, 734256.	4.8	2
171	Cefepime and mortality. <i>Lancet Infectious Diseases</i> , The, 2009, 9, 585-586.	9.1	1
172	OPO43D CULTURE OF MURINE NEURAL STEM CELLS ON DECELLULARIZED MOUSE BRAIN SECTIONS. <i>Neuro-Oncology</i> , 2015, 17, viii16.4-viii16.	1.2	1
173	Induction of HIV-specific T-cell responses by gag. <i>Retrovirology</i> , 2006, 3, S78.	2.0	0
174	Stimulation of antiviral cellular immune responses by therapeutic vaccination of HIV-1-infected patients with dendritic cells transfected with gag, tat, rev and nef mRNA. <i>Retrovirology</i> , 2011, 8, P76.	2.0	0
175	Dendritic Cells in Hematopoietic Stem Cell Transplantation. , 0, , .		0
176	Electroporating Human Corneal Epithelial Cells With Interleukin 10 and Fas Ligand pDNA. <i>Asia-Pacific Journal of Ophthalmology</i> , 2014, 3, 56-63.	2.5	0
177	The Toughest Nut to Crack: Will We Ever Have a Preventive and Effective HIV-1 Vaccine?. <i>Molecular Therapy</i> , 2016, 24, 1896-1897.	8.2	0
178	HLA Class II Genotype Does Not Affect the Myelin Responsiveness of Multiple Sclerosis Patients. <i>Cells</i> , 2020, 9, 2703.	4.1	0
179	Immunotargetting of the Wilmsâ€™ Tumor WT1 Antigen for Dendritic Cell and B-Cell-Based Vaccination of Leukemia.. <i>Blood</i> , 2004, 104, 2541-2541.	1.4	0
180	The Survival of Multiple Myeloma Patients: A Single Institution Study.. <i>Blood</i> , 2004, 104, 5223-5223.	1.4	0

#	ARTICLE	IF	CITATIONS
181	RNA Electroporation as a New Gene Transfer Method in Hematopoietic Progenitor Cells, Mesenchymal Cells and Activated T-Cells.. Blood, 2004, 104, 5269-5269.	1.4	0
182	Activation of HIV-1-Specific CD8+ and CD4+ Autologous Memory T-Cells by Dendritic Cells and B-Cells Electroporated with mRNA Encoding Consensus or Autologous HIV-1 Proteins.. Blood, 2005, 106, 326-326.	1.4	0
183	Bone marrow histology in CALR mutated thrombocythemia and myelofibrosis: results from two cross sectional studies in 70 newly diagnosed JAK2/MPL wild type thrombocythemia patients. , 2019, 2, 064-078.		0
184	Mycosis fungoides of the vulva. Ä°stanbul Kuzey Klinikleri, 2020, 8, 101-105.	0.3	0